The distinctive tumor phenotype can be exploited for targeting genetic therapies also; functionalization of nanoparticles with anti-prostate-specific membrane antigen (PSMA) RNA aptamer facilitated precise miRNA delivery to xenografts following systemic administration, and impressive tumor growth delay (Binzel et al. 2016). This evidence concerns the gene FOLH1 and neoplasm.